A Phase 4 interventional study of Rimegepant and Placebo in Migraine, sponsored by Pfizer. Completed at 93 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing rimegepant in Migraine Disorders — 13 open to participants now, 15 under way, 6 of them phase 3. rimegepant · Migraine Disorders.
Among the 32 studies testing rimegepant in Migraine Disorders, this one is the 12th largest by enrollment, is one of 8 that started in 2022, is one of 9 in phase 4, and was the 17th registered.
1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.
Browse Migraine Disorders studies →13 of the 32 studies testing rimegepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:
University of South Florida · Sites in United States
Ages 18+ · Healthy volunteers
Pfizer · Sites in United States, Israel
Ages 18+
Pfizer · Sites in India
Ages 18+
Pfizer · Sites in United States, Israel
Ages 18+
Medstar Health Research Institute · Sites in United States
Ages 18+
By country, each count listing its studies:
rimegepant: first FDA approval 2020 (NURTEC ODT), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 16 · Phase 4 9
First in 2011; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 813 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.
Median enrollment 618 across the 32 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 8 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
47 studies in Migraine Disorders by Pfizer: 10 open now, 14 under way, 6 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 47 studies in Migraine Disorders by Pfizer, this one is the 17th largest by enrollment of the 37 interventional ones that give a count, is one of 8 that started in 2022, is one of 6 in phase 4, and was the 28th registered.
Pfizer’s Migraine Disorders studies by the year they started, since 2007.
3 of the studies testing rimegepant in Migraine Disorders that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641466Phase 3PfizerA Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | 2026-11-29 |
| NCT07918053Chinese PLA General HospitalA Prospective Study of Rimegepant for Short-term Preventive Treatment of Night-shift-related Migraine in Healthcare Professionals | 2027-06 |
| NCT07667621University of South FloridaA Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies testing rimegepant in Migraine Disorders, from their registry updates:
Among Pfizer’s 47 in Migraine Disorders:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease).
This study is being conducted to evaluate the efficacy and tolerability of rimegepant in a population of adults that are unsuitable for triptan medications due to a previous intolerance, lack of efficacy, or contraindication (including a history of clinically-relevant cardiovascular disease). Rimegepant will be further evaluated in this population with as needed use in a 12-week, open-label extension study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
-Target Disease Exclusion:
Rimegepant - Double-blind (DB) Phase: One dose of rimegepant 75 mg Oral Disintegrating Tablet (ODT) Rimegepant/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT as needed for a qualifying acute migraine. A qualifying migraine is an attack of moderate or severe headache pain intensity. Migraine headache pain intensity will be measured on a 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe)
Drug: Rimegepant
Placebo - Double-blind (DB) Phase: One dose of matching placebo Placebo/Rimegepant - Open-label Extension (OLE) Phase: participants receive one dose rimegepant 75 mg ODT for a qualifying migraine
Drug: Placebo · Drug: Rimegepant
DB Phase: Rimegepant 75 mg Orally Disintegrating Tablet (ODT)
DB Phase: matching placebo
OLE Phase: Rimegepant 75 mg ODT in association with each of the first 5 qualifying migraines
Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain relief at 2 hours post-dose was defined as pain intensity of none or mild at that time point.
Time frame: At 2 hours post-dose
Percentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain freedom at 2 hours post-dose was a pain intensity of none at that time point.
Time frame: At 2 hours post-dose
Percentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase
Post 24 hours after dosing with study medication and after the 24-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: 1) non-steroidal anti-inflammatory drug like acetaminophen or aspirin, ibuprofen, naproxen; 2) antiemetics like metoclopramide, promethazine; 3) other like baclofen; 4) other approved pharmacological treatment with established efficacy in the acute treatment of migraine, including locally recognized standard of care, unless otherwise specified.
Time frame: Within 24 hours post-dose
Percentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Return to normal function at 2 hours post-dose was defined as functional disability score of normal at that time point for participants with functional disability at the time of dosing.
Time frame: At 2 hours post-dose
Percentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 24 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 24 hours post-dose in participants with functional disability at the time of dosing.
Time frame: From 2 to 24 hours post-dose
Percentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 48 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 48 hours post-dose in participants with functional disability at the time of dosing.
Time frame: From 2 to 48 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose.
Time frame: From 2 to 24 hours post-dose
Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose.
Time frame: From 2 to 48 hours post-dose
Percentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose.
Time frame: From 2 to 24 hours post-dose
Percentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose.
Time frame: From 2 to 48 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase
MBS freedom was defined as MBS reported before dosing that was absent post-dose at the specified time point. MBS reported before dosing was nausea, photophobia, or phonophobia. Each symptom (nausea, photophobia, or phonophobia) was measured post-dose using 0= absent or 1= present. Participants who had symptom score of 0 (absent) aligning with MBS reported before dosing were considered to have MBS freedom.
Time frame: At 2 hours post-dose
Reliability of Rimegepant Effect in the OLE Phase Based on Evaluable Qualifying Migraine Attacks (EQMA) of DBT and OLE Phase
Reliability of rimegepant effect during OLE Phase achieved when difference between (1) percentage of participants randomized to rimegepant with response to single EQMA in DBT phase and(2) percentage of participants with response to \>=4 of first 5 EQMAs \>=23 hours(h) apart in OLE phase was \<=7%. Statistical analysis reports difference between (1) and (2) for each first 5 EQMAs \>=23h apart in OLE phase. Response: category of "moderately better" or"very much better" for Migraine Quality of Life Questionnaire(MQoL)Question(Q) 16 (overall change in migraine symptoms since taking study medication) at 24h post-dose. EQMA:evaluable qualifying migraine attack (migraine attack of moderate/severe pain intensity,first treated with rimegepant, not other acute headache medication) with nonmissing MQoL Q16 value at 24h post dose. Percentage of participants with response after single EQMA in DBT phase randomized to rimegepant and each of first 5 EQMA in OLE phase are reported in descriptive section.
Time frame: DBT phase: up to maximum 45 days; OLE phase: up to maximum of 12 weeks
Mean Change From Historical Baseline in Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase
Mean change from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) at each specified month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history case report form (CRF). Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.
Time frame: Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)
Percentage of Participants With at Least 50% Reduction From Historical Baseline in the Number of Migraine Days Per Month by Headache Pain Intensity at Months 1, 2 and 3 and Overall: OLE Phase
Percentages of participants with \>= 50% reduction from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) in each month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history CRF. Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.
Time frame: Baseline (3 months prior to Screening); Month 1 (OLE Days 1 to 28), Month 2 (OLE Days 29 to 56) and Month 3 (OLE Days 57 to 84), and Overall OLE phase (84 days)
Number of Participants With Adverse Events (AEs) by Intensity: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.
Time frame: DBT Phase: maximum of 45 days
Number of Participants With Serious AEs: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.
Time frame: DBT Phase: maximum of 45 days
Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.
Time frame: DBT Phase: maximum of 45 days
Number of Participants With Any On-Treatment Grade 3 to 4 Laboratory Abnormalities: DBT Phase
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.
Time frame: DBT Phase: maximum of 45 days
Number of Participants With AEs by Intensity: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.
Time frame: OLE Phase: maximum up to 12 weeks
Number of Participants With Serious AEs: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.
Time frame: OLE Phase: maximum up to 12 weeks
Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.
Time frame: OLE Phase: maximum up to 12 weeks
Number of Participants With On-Treatment Grade 3 to 4 Laboratory Abnormalities: OLE Phase
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.
Time frame: OLE Phase: maximum up to 12 weeks
Mean Change From Baseline in the Migraine Interictal Burden Scale (MIBS) Score at Weeks 4, 8, and 12: OLE Phase
MIBS was a 4-item self-administered questionnaire that measured interictal migraine related burden in the past 4 weeks on days when participants were not having an attack, using 4 domains: impairment in work or school; impairment in family and social life; difficulty making plans or commitments; emotional/affective and cognitive distress. The questionnaire specifically asked about the effect of the disease over the past 4 weeks on days without a headache attack. Response options included: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each response associated with numerical score were summed across all 4 items resulting in a total MIBS score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none and 12 for severe. Higher scores indicate worse interictal burden.
Time frame: OLE phase: Baseline; Week 4, Week 8 and Week 12
A total of 813 participants were enrolled in the study, out of these 180 participants were not randomized. Only 633 participants were randomized. A total of 585 participants were treated with study intervention in double-blind treatment (DBT) phase. Then, 555 participants continued into open label extension (OLE) phase.
| Milestone | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Started | 317 | 316 |
| Treated | 295 | 290 |
| Completed | 286 | 283 |
| Not completed | 31 | 33 |
| Withdrew: Non-compliance with study drug | 4 | 2 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Withdrawal by subject | 4 | 7 |
| Withdrew: Randomized but not treated | 19 | 22 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Started | 281 | 274 |
| Treated | 281 | 271 |
| Completed | 265 | 254 |
| Not completed | 16 | 20 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Other | 3 | 2 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Protocol violation | 3 | 0 |
| Withdrew: Withdrawal by subject | 5 | 11 |
| Withdrew: Failure to meet continuation criteria | 0 | 2 |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain relief at 2 hours post-dose was defined as pain intensity of none or mild at that time point.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Pain Relief at 2 Hours Post-Dose: DBT Phase | 55.9 (50.2 to 61.7) | 32.7 (27.3 to 38.2) |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Pain freedom at 2 hours post-dose was a pain intensity of none at that time point.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Pain Freedom at 2 Hours Post-Dose: DBT Phase | 22.7 (17.9 to 27.6) | 7.4 (4.4 to 10.4) |
Post 24 hours after dosing with study medication and after the 24-hour assessments were completed on the e-diary, participants were permitted to use the following rescue medications (non-study medications) such as: 1) non-steroidal anti-inflammatory drug like acetaminophen or aspirin, ibuprofen, naproxen; 2) antiemetics like metoclopramide, promethazine; 3) other like baclofen; 4) other approved pharmacological treatment with established efficacy in the acute treatment of migraine, including locally recognized standard of care, unless otherwise specified.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants Who Used Rescue Medications Within 24 Hours Post-Dose: DBT Phase | 18.0 (13.5 to 22.5) | 46.2 (40.4 to 52.1) |
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Return to normal function at 2 hours post-dose was defined as functional disability score of normal at that time point for participants with functional disability at the time of dosing.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Return to Normal Function at 2 Hours Post-Dose: DBT Phase | 28.9 (23.0 to 34.7) | 12.7 (8.4 to 16.9) |
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 24 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 24 hours post-dose in participants with functional disability at the time of dosing.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Return to Normal Function From 2 to 24 Hours Post-Dose: DBT Phase | 18.1 (13.1 to 23.1) | 6.8 (3.6 to 9.9) |
Functional disability level was measured on a 4-point numeric rating scale (0= normal,1= mildly impaired, 2= severely impaired, 3= required bedrest). Functional disability was defined as a functional disability level of mildly impaired, severely impaired, or required bedrest. Sustained return to normal function, from 2 to 48 hours post-dose was defined as functional disability levels of normal at all time points from 2 to 48 hours post-dose in participants with functional disability at the time of dosing.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Return to Normal Function From 2 to 48 Hours Post-Dose: DBT Phase | 15.9 (11.2 to 20.7) | 4.2 (1.7 to 6.8) |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 24 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 24 hours post-dose.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours Post-Dose: DBT Phase | 38.8 (33.2 to 44.5) | 14.4 (10.3 to 18.5) |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain relief from 2 to 48 hours post-dose was defined as a pain intensity of none or mild at all time points from 2 to 48 hours post-dose.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Pain Relief From 2 to 48 Hours Post-Dose: DBT Phase | 33.9 (28.4 to 39.4) | 10.6 (7.0 to 14.1) |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 24 hours post-dose was defined as a pain intensity of none at all time points from 2 to 24 hours post-dose.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Freedom From Pain From 2 to 24 Hours Post-Dose: DBT Phase | 14.0 (10.0 to 18.0) | 4.9 (2.4 to 7.4) |
Participants recorded their migraine headache pain intensity using 4-point numeric rating scale (0=none, 1=mild, 2=moderate, 3=severe). Sustained pain freedom from 2 to 48 hours post-dose was defined as a pain intensity of none at all time points from 2 to 48 hours post-dose.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Sustained Freedom From Pain From 2 to 48 Hours Post-Dose: DBT Phase | 12.2 (8.4 to 16.0) | 2.8 (0.9 to 4.7) |
MBS freedom was defined as MBS reported before dosing that was absent post-dose at the specified time point. MBS reported before dosing was nausea, photophobia, or phonophobia. Each symptom (nausea, photophobia, or phonophobia) was measured post-dose using 0= absent or 1= present. Participants who had symptom score of 0 (absent) aligning with MBS reported before dosing were considered to have MBS freedom.
| Percentage of participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-Dose: DBT Phase | 31.1 (25.8 to 36.5) | 18.7 (14.1 to 23.2) |
Reliability of rimegepant effect during OLE Phase achieved when difference between (1) percentage of participants randomized to rimegepant with response to single EQMA in DBT phase and(2) percentage of participants with response to \>=4 of first 5 EQMAs \>=23 hours(h) apart in OLE phase was \<=7%. Statistical analysis reports difference between (1) and (2) for each first 5 EQMAs \>=23h apart in OLE phase. Response: category of "moderately better" or"very much better" for Migraine Quality of Life Questionnaire(MQoL)Question(Q) 16 (overall change in migraine symptoms since taking study medication) at 24h post-dose. EQMA:evaluable qualifying migraine attack (migraine attack of moderate/severe pain intensity,first treated with rimegepant, not other acute headache medication) with nonmissing MQoL Q16 value at 24h post dose. Percentage of participants with response after single EQMA in DBT phase randomized to rimegepant and each of first 5 EQMA in OLE phase are reported in descriptive section.
| Percentage of participants | DB Rimegepant | OL Rimegepant |
|---|---|---|
| DBT Phase EQMA | 64.2 (58.2 to 70.2) | — |
| OLE Phase First EQMA | — | 65.1 (61.0 to 69.2) |
| OLE Phase Second EQMA | — | 66.9 (62.8 to 71.0) |
| OLE Phase Third EQMA | — | 69.1 (65.0 to 73.2) |
| OLE Phase Fourth EQMA | — | 70.8 (66.5 to 75.0) |
| OLE Phase Fifth EQMA | — | 71.1 (66.3 to 75.8) |
Mean change from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) at each specified month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history case report form (CRF). Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.
| Migraine days per month | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Total historical baseline | 7.8 ± 2.56 | 7.8 ± 2.57 |
| Total: Change at Month 1 | -3.3 ± 3.51 | -3.6 ± 3.45 |
| Total: Change at Month 2 | -2.3 ± 3.74 | -2.7 ± 3.81 |
| Total: Change at Month 3 | -2.1 ± 3.76 | -2.5 ± 4.01 |
| Total: Change in overall OLE phase | -2.6 ± 3.31 | -3.0 ± 3.37 |
| Moderate or severe historical baseline | 6.7 ± 2.44 | 6.6 ± 2.56 |
| Moderate or severe: Change at Month 1 | -2.4 ± 3.63 | -2.6 ± 3.49 |
| Moderate or severe: Change at Month 2 | -1.3 ± 4.00 | -1.7 ± 3.79 |
| Moderate or severe: Change at Month 3 | -1.0 ± 4.02 | -1.5 ± 4.09 |
| Moderate or severe: Change in overall OLE phase | -1.6 ± 3.57 | -1.9 ± 3.40 |
Percentages of participants with \>= 50% reduction from historical baseline in the number of migraine days per month by headache pain intensity (total; moderate or severe) in each month and over the entire OLE Phase is reported in this outcome measure. A migraine day was defined as either 1) a day on which participant experienced migraine headache pain intensity of mild, moderate, or severe as reported in eDiary or 2) an acute migraine-specific medication day. Total historical baseline is defined as the number of migraine days per month of any pain intensity in the 3 months prior to screening from the migraine history CRF. Moderate or severe historical baseline was defined as the number of migraine days per month of moderate or severe pain intensity in the 3 months prior to screening from the migraine history CRF.
| Percentage of participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Total: Change at Month 1 | 50.7 | 57.9 |
| Total: Change at Month 2 | 42.1 | 43.3 |
| Total: Change at Month 3 | 40.5 | 42.2 |
| Total: Change in overall OLE phase | 36.2 | 41.7 |
| Moderate or severe: Change at Month 1 | 47.5 | 49.6 |
| Moderate or severe: Change at Month 2 | 37.3 | 37.5 |
| Moderate or severe: Change at Month 3 | 32.4 | 35.9 |
| Moderate or severe: Change in overall OLE phase | 33.7 | 35.0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Mild | 31 (25.8 to 36.5) | 19 (14.1 to 23.2) |
| Moderate | 6 | 15 |
| Severe | 0 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Number of Participants With Serious AEs: DBT Phase | 0 (25.8 to 36.5) | 0 (14.1 to 23.2) |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation: DBT Phase | 0 (25.8 to 36.5) | 0 (14.1 to 23.2) |
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.
| Participants | DB Rimegepant | DB Placebo |
|---|---|---|
| Eosinophils, high | 0 | 0 |
| Hemoglobin, high | 0 | 0 |
| Hemoglobin, low | 0 | 0 |
| Leukocytes, low | 0 | 0 |
| Lymphocytes, high | 0 | 0 |
| Lymphocytes, low | 0 | 0 |
| Neutrophils, low | 0 | 0 |
| Platelets, low | 0 | 0 |
| Alanine Aminotransferase, high | 0 | 0 |
| Alkaline Phosphatase, high | 0 | 0 |
| Aspartate Aminotransferase, high | 0 | 0 |
| Bicarbonate, low | 0 | 0 |
| Bilirubin, high | 0 | 0 |
| Creatinine, high | 0 | 0 |
| Glucose, high | 0 | 0 |
| Glucose, low | 0 | 0 |
| Potassium, high | 0 (25.8 to 36.5) | 1 (14.1 to 23.2) |
| Potassium, low | 0 | 0 |
| Sodium, high | 0 | 0 |
| Sodium, low | 0 | 0 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. AE intensity included mild, moderate and severe. Mild AE was defined as AEs which is usually transient and required only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living. Moderate AE was defined as AEs which was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the participants. Severe AE was defined as AE that interrupted with usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Mild | 97 | 86 |
| Moderate | 65 | 53 |
| Severe | 1 | 2 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. A serious AE is any event that met any of the following criteria at any dose: death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect in the offspring of a participant who received rimegepant or other important medical events.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Number of Participants With Serious AEs: OLE Phase | 1 | 1 |
An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participants or clinical investigation participant administered an investigational (medicinal) product and that does not necessarily have a causal relationship with the treatment. Number of participants with AEs leading to study drug discontinuation have been reported in this outcome measure.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Number of Participants With AEs Leading to Study Drug Discontinuation: OLE Phase | 3 | 2 |
Laboratory tests included hematology and serum chemistry. All laboratory tests except glucose were graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, where Grade 3=severe events which require hospitalization or prolongation of hospitalization and Grade 4=life-threatening consequences requiring urgent intervention. Glucose was graded according to Division of Acquired Immune Deficiency Syndrome table for Grading Severity of Adult and Pediatric Adverse Events v2.1.
| Participants | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Eosinophils, high | 0 | 0 |
| Hemoglobin, high | 0 | 0 |
| Hemoglobin, low | 0 | 0 |
| Leukocytes, low | 1 | 0 |
| Lymphocytes, high | 0 | 0 |
| Lymphocytes, low | 1 | 0 |
| Neutrophils, low | 3 | 0 |
| Platelets, low | 0 | 0 |
| Alanine Aminotransferase, high | 0 | 0 |
| Alkaline Phosphatase, high | 0 | 0 |
| Aspartate Aminotransferase, high | 0 | 0 |
| Bicarbonate, low | 0 | 0 |
| Bilirubin, high | 0 | 0 |
| Creatinine, high | 0 | 0 |
| Glucose, high | 1 | 0 |
| Glucose, low | 0 | 0 |
| Potassium, high | 0 | 0 |
| Potassium, low | 0 | 0 |
| Sodium, high | 0 | 0 |
| Sodium, low | 0 | 0 |
MIBS was a 4-item self-administered questionnaire that measured interictal migraine related burden in the past 4 weeks on days when participants were not having an attack, using 4 domains: impairment in work or school; impairment in family and social life; difficulty making plans or commitments; emotional/affective and cognitive distress. The questionnaire specifically asked about the effect of the disease over the past 4 weeks on days without a headache attack. Response options included: don't know/not applicable (0), never (0), rarely (1), some of the time (2), much of the time (3), or most or all of the time (3). Each response associated with numerical score were summed across all 4 items resulting in a total MIBS score ranging from 0 to 12, and the level of interictal burden being categorized into the following: 0 for none and 12 for severe. Higher scores indicate worse interictal burden.
| Scores on a scale | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant |
|---|---|---|
| Change at week 4 | -0.8 ± 3.01 | -1.1 ± 3.02 |
| Change at week 8 | -1.0 ± 3.17 | -1.3 ± 3.04 |
| Change at week 12 | -1.1 ± 3.28 | -1.5 ± 3.46 |
Collected over DBT Phase: maximum of 45 days; OLE Phase: maximum up to 12 weeks; Follow-up phase: 2 weeks after the discontinuation or completion of the OLE phase; Post-DBT Pre-OLE (Interim) phase: OL rimegepant start date - DB study drug date > 9 days (up to 13 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Rimegepant: DBT Phase | 0/295 (0%) | 0/295 (0%) | 116/295 (39.3%) |
| DB Placebo: DBT Phase | 0/290 (0%) | 0/290 (0%) | 20/290 (6.9%) |
| DB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE Phase | 0/253 (0%) | 0/253 (0%) | 0/253 (0%) |
| DB Placebo/OL Rimegepant: Post-DBT Pre-OLE Phase | 0/244 (0%) | 0/244 (0%) | 0/244 (0%) |
| DB Rimegepant/ OL Rimegepant: OLE Phase | 0/281 (0%) | 1/281 (0.4%) | 68/281 (24.2%) |
| DB Placebo/ OL Rimegepant: OLE Phase | 0/271 (0%) | 1/271 (0.4%) | 56/271 (20.7%) |
| DB Rimegepant/ OL Rimegepant: Follow-up Phase | 0/283 (0%) | 1/283 (0.4%) | 67/283 (23.7%) |
| DB Placebo/ OL Rimegepant: Follow-up Phase | 0/267 (0%) | 2/267 (0.7%) | 55/267 (20.6%) |
| Event | DB Rimegepant: DBT Phase | DB Placebo: DBT Phase | DB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE Phase | DB Placebo/OL Rimegepant: Post-DBT Pre-OLE Phase | DB Rimegepant/ OL Rimegepant: OLE Phase | DB Placebo/ OL Rimegepant: OLE Phase | DB Rimegepant/ OL Rimegepant: Follow-up Phase | DB Placebo/ OL Rimegepant: Follow-up Phase |
|---|---|---|---|---|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/295 | 0/290 | 0/253 | 0/244 | 0/281 | 0/271 | 0/283 | 1/267 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/295 | 0/290 | 0/253 | 0/244 | 1/281 | 0/271 | 1/283 | 1/267 |
| Suicidal IdeationPsychiatric disorders | 0/295 | 0/290 | 0/253 | 0/244 | 0/281 | 1/271 | 0/283 | 0/267 |
| Event | DB Rimegepant: DBT Phase | DB Placebo: DBT Phase | DB Rimegepant/OL Rimegepant: Post-DBT Pre-OLE Phase | DB Placebo/OL Rimegepant: Post-DBT Pre-OLE Phase | DB Rimegepant/ OL Rimegepant: OLE Phase | DB Placebo/ OL Rimegepant: OLE Phase | DB Rimegepant/ OL Rimegepant: Follow-up Phase | DB Placebo/ OL Rimegepant: Follow-up Phase |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 72/295 | 11/290 | 0/253 | 0/244 | 44/281 | 36/271 | 43/283 | 35/267 |
| Upper respiratory tract infectionInfections and infestations | 29/295 | 1/290 | 0/253 | 0/244 | 18/281 | 12/271 | 18/283 | 12/267 |
| HeadacheNervous system disorders | 27/295 | 10/290 | 0/253 | 0/244 | 16/281 | 17/271 | 16/283 | 17/267 |
Safety analysis set (SAS) included participants in the enrolled analysis set who took \>= 1 dose of study drug. Enrolled analysis set included participants who signed an informed consent form and were assigned a participant identification number, i.e., non-missing informed consent date.
| Age, Continuous(Years) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Mean | 43.0 ± 11.79 | 42.7 ± 11.50 | 42.9 ± 11.64 |
| Sex: Female, Male(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Female | 260 | 261 | 521 |
| Male | 35 | 29 | 64 |
| Race/Ethnicity, Customized(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| White | 53 | 45 | 98 |
| Black or African American | 5 | 8 | 13 |
| Multiracial | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | DB Rimegepant/ OL Rimegepant | DB Placebo/ OL Rimegepant | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 15 |
| Not Hispanic or Latino | 50 | 46 | 96 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Oct 2022 to primary completion in Mar 2025, 28 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
Of 28 industry-sponsored phase 4 interventional studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 33. This study's 28 months is close to that.
Counting every sponsor, half of 77 studies reached it within 27 months; a quarter within 17 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant